.png)
.png)
Registering and protecting pharmaceutical trademarks in the Philippines can be more challenging than registering marks for ordinary consumer goods. This is because pharmaceutical brands have to pass through two different authorities:
For drug companies, this means your brand name must not only be unique and protectable under trademark law, but it must also meet FDA rules designed to prevent confusion and ensure patient safety.
Generic names of medicines (like “paracetamol”) can never be trademarked in the Philippines because they belong to the public. What you can protect is the brand name—for example, “Biogesic®.”
When filing a trademark application with IPOPHL, you can’t simply claim rights over “all medicines.” You need to specify exactly what kind of pharmaceutical products you want protection for, such as “antibiotics for respiratory infections” or “antihypertensive preparations.” This makes your application stronger and avoids conflicts with other drug makers.
Unlike trademarks for clothing or gadgets, pharmaceutical trademarks are judged under stricter standards. Even small similarities can be a problem because confusion between two drugs can have life-threatening consequences.
For example, in a dispute involving Pfizer’s Lipitor and a competing brand called Liprimar, IPOPHL carefully considered the risk that patients might confuse one for the other. In cases like this, even if the marks look or sound only slightly alike, IPOPHL may reject a new application to protect public health.
Pharmaceutical companies can also rely on copyright law for things like packaging design, logos, and patient information leaflets. While the trademark protects the name, copyright ensures that your written materials, designs, and even certain graphics cannot be copied.
This combination of trademark and copyright helps brand owners fight counterfeiting more effectively.
In some cases, pharmaceutical companies have tried to protect things like the shape or color of a pill. IPOPHL does allow registration of non-traditional marks such as 3D shapes, colors, and even sounds—so long as they are distinctive and not functional.
For example, if a tablet’s triangular shape is widely recognized as belonging to a particular company, IPOPHL may accept it as a trademark. But functional features, such as sugar coatings for easier swallowing, cannot be registered because they serve a practical purpose.
Counterfeit medicines are a big issue in the Philippines. To fight this, IPOPHL works closely with the FDA and Bureau of Customs. Many companies now use track-and-trace systems, holograms, or QR codes to help patients and pharmacists verify authenticity.
In one notable case, IPOPHL ruled in favor of a global drug manufacturer when counterfeit versions of its cancer drug appeared in local markets. The ruling highlighted how trademarks, combined with strict FDA rules, can protect both brand owners and patients from dangerous fakes.
The Philippines is stricter than countries like the U.S. when it comes to direct-to-consumer drug advertising. Prescription-only medicines cannot be freely advertised to the general public. Instead, ads must be targeted at medical professionals, and even then, they must be balanced, truthful, and not misleading.
This means pharmaceutical companies rely heavily on doctors and pharmacists to convey information about their products to patients, rather than mass-market ads.
With the rise of online shopping, fake or unlicensed online pharmacies have also become a problem. IPOPHL allows trademark owners to challenge bad-faith domain registrations (like “biojesic.com”) through domain dispute proceedings.
Meanwhile, the FDA has launched public awareness campaigns warning consumers to only buy from licensed online pharmacies. Safe sites are required to have proper FDA approval, a licensed pharmacist available for consultation, and valid prescriptions from doctors.
Protecting pharmaceutical trademarks in the Philippines is not just about brand ownership—it’s about public safety. Companies must navigate IPOPHL’s trademark system, FDA’s naming rules, and strict advertising restrictions.
The most successful strategy combines:
Cases like Lipitor vs. Liprimar show how seriously the Philippine system takes the risk of consumer confusion. In the end, protecting your brand also protects patients—and that’s why the bar is set so high.